-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $120

Benzinga·10/19/2026 17:51:11
Listen to the news
BMO Capital analyst Evan David Seigerman maintains Disc Medicine (NASDAQ:IRON) with a Outperform and raises the price target from $100 to $120.